Related Experiment Video

Updated: Jul 4, 2026

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

[Value of targeted therapies for renal cell cancer]

A S Merseburger1, M A Kuczyk

  • 1Klinik für Urologie und Urologische Onkologie, Medizinische Hochschule, Carl-Neuberg-Strasse 1, 30625 Hannover, Deutschland.

Der Urologe. Ausg. A
|July 1, 2008
PubMed

Insights

Cytokine therapy is no longer the primary choice for metastatic renal cancer. Targeted therapies, including multikinase inhibitors and monoclonal antibodies, show promising results and are increasingly used.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Medicine

Background:

  • Cytokine therapy for metastatic renal cancer has limitations in clinical response.
  • Emerging molecular targeted therapies offer promising alternatives.

Purpose of the Study:

  • To critically review available clinical data on targeted therapeutics for metastatic renal cell cancer (RCC).
  • To discuss the current landscape of targeted therapies in metastatic RCC treatment.

Main Methods:

  • Review of randomized controlled studies on targeted therapies for metastatic renal cancer.
  • Analysis of clinical data for approved drugs like sorafenib, sunitinib, temsirolimus, and bevacizumab.

Main Results:

  • Sorafenib, sunitinib, temsirolimus, and bevacizumab (with interferon-alpha) have substantial approval data.
  • Sunitinib, temsirolimus, and bevacizumab are approved for first-line treatment; sorafenib for second-line.

Conclusions:

  • Targeted therapies are becoming the standard of care for metastatic renal cancer.
  • Future research focuses on optimal timing, sequencing, and patient preselection for individualized therapy.

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.